CDXS

Several events have impacted Codexis' stock price in the past six months. In November 2025, Codexis announced its Q3 2025 financial results, reporting decreased revenues but also announced a Supply Assurance Agreement with Merck and organizational changes, including a workforce reduction. A leadership transition also occurred, with Dr. Alison Moore succeeding Dr. Stephen Dilly as CEO. In May 2026, Codexis reported strong Q1 2026 financial results, with increased revenues and a narrowed net loss, reiterating its full-year 2026 revenue guidance. As of May 7, 2026, Codexis' stock price was $2.58, representing a 4.88% increase over the past year and a significant increase since the beginning of 2026. In the past three months, there has been no insider buying activity, but one insider selling transaction was noted.